Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Median Survival Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction Prescribed Quadruple Medical Therapy.
Journal: European journal of heart failure
Published: February 05, 2026
One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.
Journal: JAMA cardiology
Published: January 28, 2026
Clinical Evaluation of Drug-Drug Interactions With Aficamten.
Journal: Clinical and translational science
Published: November 24, 2025
Residual Risk Despite Quadruple Medical Therapy for Men vs Women Hospitalized for Heart Failure With Reduced Ejection Fraction.
Journal: JACC. Heart failure
Published: September 29, 2025
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.
Journal: European journal of heart failure
Published: September 22, 2025
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF.
Journal: JACC. Heart failure
Published: September 12, 2025
Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.
Journal: Clinical pharmacokinetics
Published: August 23, 2025
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.
Journal: European journal of heart failure
Published: August 19, 2025
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Journal: European journal of heart failure
Published: August 11, 2025
Last Updated: 09/26/2026